Last update:

HIV & AIDS news

HIV & AIDS

Early HIV drugs give immune system a brief reprieve before dysregulation returns, study finds

Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term.

HIV & AIDS

Low-dose THC may reduce side effects of HIV treatment

Long-term, low doses of THC mitigate many harmful side effects and inflammation caused by HIV and antiretroviral therapy (ART), according to new research from Texas Biomedical Research Institute.

HIV & AIDS

Early HIV treatment: Research reveals critical gaps

In an article published in The Lancet HIV, authors including Distinguished Professor Denis Nash and Professor Constantin Yiannoutsos aim to provide the most comprehensive estimates of pediatric mortality among children and ...

HIV & AIDS

How HIV disrupts sleep across Africa

HIV significantly affects sleep, with many affected people living in a state akin to chronic jet lag. A new study with Wits researchers published in The Lancet HIV describes how people living with HIV (PLWHIV) experience ...

HIV & AIDS

Oral health in HIV+ population

Pushpa Pandiyan, associate professor of biological sciences in the School of Dental Medicine, and a team of researchers have been working to discover the cause behind residual systemic inflammation and dysfunction of the ...

HIV & AIDS

Investigating mechanisms behind early HIV-1 infection

Northwestern Medicine investigators have discovered that a microtubule regulatory protein inhibits early HIV type 1 (HIV-1) infection, according to findings published in Proceedings of the National Academy of Sciences.

HIV & AIDS

Treatment strategy may lead to HIV cure

Armed with a novel strategy they developed for bolstering the body's immune response, scientists at Albert Einstein College of Medicine have successfully suppressed HIV infections in mice—offering a path to a functional ...

HIV & AIDS

Partnering with traditional healers boosts HIV testing in Uganda

Collaborating with traditional healers to deliver point-of-care HIV tests to individuals in rural Uganda quadrupled testing rates compared with standard referrals to HIV clinics, according to a trial by Weill Cornell Medicine ...

Oncology & Cancer

Solving mystery of rare cancers directly caused by HIV

For nearly a decade, scientists have known that HIV integrates itself into genes in cells that have the potential to cause cancer. And when this happens in animals with other retroviruses, those animals often develop cancer. ...

Medications

Awareness of, referral to HIV PrEP low among Hispanics

(HealthDay)—About one in four Hispanic persons tested for HIV are aware of preexposure prophylaxis (PrEP) and about one in five of those eligible for referral are referred to PrEP providers, according to research published ...

HIV & AIDS

In COVID's shadow, HIV on march in Eastern Europe

In a Bucharest back street, drug addicts rush towards an ambulance handing out free syringes. While the eyes of the world focus on the COVID-19 pandemic, the fight against HIV has slowed down in Eastern Europe.

HIV & AIDS

A novel method to block HIV in mice

Researchers at City of Hope, a world-renowned research and treatment organization for cancer and diabetes, and Menzies Health Institute Queensland at Griffith University have developed a novel anti-HIV protein that suppressed ...

HIV & AIDS

Impaired T cell function precedes loss of natural HIV control

HIV is a master of evading the immune system, using a variety of methods to prevent the body from being able to find and kill it. The vast majority of people living with HIV require daily medication to suppress the virus ...

HIV & AIDS

HIV linked with increased risk of sudden cardiac death

People living with human immunodeficiency virus (HIV) have a higher risk of sudden cardiac death than people who do not have HIV, especially if the virus is not well-controlled or if they have other heart disease risk factors, ...

HIV & AIDS

HIV prevention treatment shows gaps among key populations

A large, detailed look at patients taking HIV-prevention drug therapy finds strong adherence soon after patients get the prescription, but less consistent use thereafter, particularly among groups considered high priority ...

HIV & AIDS

Among persons with HIV, more finish short-course TB prophylaxis

(HealthDay)—Tuberculosis preventive treatment completion is higher with three months of rifapentine-isoniazid than six months of isoniazid among patients with HIV receiving antiretroviral therapy, according to a study published ...